Hypericum perforatum

Within the SIRIAM Platform, Hypericum perforatum is classified as a Regional Signature Component.

Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, Hypericum perforatum is incorporated selectively into regional formulations according to their intended neurodermal objectives.

Within the SIRIAM formulation philosophy, Regional Signature Components provide the anatomical individuality of each formulation. Hypericum perforatum therefore contributes to the functional identity of selected regional preparations rather than to the universal pharmaceutical architecture shared across the platform.

Its inclusion reflects the platform strategy of integrating botanicals with established biological activity into anatomically targeted neurodermal formulations.

Hypericum perforatum (St. John's Wort) is a perennial medicinal plant belonging to the Hypericaceae family and has been extensively investigated in both phytotherapy and pharmaceutical research.

The principal phytochemical constituents include:

Hyperforin

Hypericin

pseudohypericin

flavonoids

phenolic acids

procyanidins

Experimental investigations have demonstrated multiple biological mechanisms, including:

modulation of inflammatory signalling pathways;

antioxidant activity;

influence on cytokine production;

stimulation of keratinocyte proliferation and differentiation;

enhancement of fibroblast activity;

promotion of collagen synthesis;

support of epithelial repair processes;

modulation of peripheral neuronal responses in experimental models.

Human clinical evidence differs substantially depending on the route of administration.

For oral administration, standardized Hypericum extracts have been extensively investigated in mild to moderate depressive disorders, with numerous systematic reviews demonstrating clinical efficacy comparable to conventional antidepressants in selected patient populations.

For topical application, clinical evidence supports beneficial effects in:

superficial wound healing;

burn management;

postoperative wound recovery;

minor skin injuries.

Several clinical studies suggest improved epithelial regeneration and symptom reduction, although formulation heterogeneity limits direct comparison.

Experimental studies have also explored potential neuroprotective and peripheral nerve regenerative properties, primarily in laboratory models. While these findings are biologically interesting, human evidence remains limited.

Importantly, hypericin possesses well-documented photosensitising properties, particularly following systemic administration. Topical preparations generally produce a substantially lower risk, but formulation concentration and patient guidance remain important pharmaceutical considerations.

Current scientific evidence evaluates Hypericum perforatum primarily as an isolated botanical extract or within conventional pharmaceutical formulations.

No published studies currently investigate its incorporation into a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform. Consequently, its inclusion reflects biological plausibility together with the architectural design philosophy of the platform rather than established evidence for this specific pharmaceutical application.

Within the SIRIAM Platform, Hypericum perforatum functions as a Regional Signature Component.

Its architectural role is to contribute to the biological identity of selected regional formulations while remaining independent of the common pharmaceutical platform shared by all SIRIAM preparations.

Future optimisation may refine extract standardisation, concentration and regional indications without altering its architectural position.